Urgent

Trousseau syndrome (cancer-associated thrombosis)

Thrombosis · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Hypercoagulability of malignancy causing recurrent, migratory or unusual-site venous (and arterial) thromboses, sometimes as the presenting feature of occult cancer.

Red flags

  • Recurrent thrombosis despite anticoagulation
  • Unusual-site thrombosis
  • Arterial events
  • Marfanoid coagulopathy / DIC features

Assessment

Differential diagnosis

  • Provoked / unprovoked venous thromboembolism
  • Antiphospholipid syndrome
  • Heparin-induced thrombocytopenia
  • Paroxysmal nocturnal haemoglobinuria
  • Vasculitis

Investigations

  • Doppler / CT to confirm thrombosis
  • FBC, coagulation, D-dimer
  • Review for underlying malignancy
  • Renal and liver function
  • Age-appropriate cancer screening

Management

  • Confirm and treat the acute thrombosis
  • Anticoagulate (low-molecular-weight heparin often preferred)
  • Assess for occult malignancy
  • Manage the underlying cancer
  • Monitor for recurrent thrombosis despite anticoagulation
  • Haematology / oncology involvement

Drugs & doses

Low-molecular-weight heparin (often preferred in cancer)
Direct oral anticoagulant in selected cancers (specialist)
Manage the underlying malignancy

Disposition

Anticoagulate; investigate for malignancy.

Complications & pitfalls

  • Recurrent thromboembolism
  • Pulmonary embolism
  • Non-bacterial thrombotic endocarditis with emboli

Exam pearls

  • Migratory or unusual-site thrombosis should prompt a cancer search.
  • LMWH has traditionally been favoured over warfarin in cancer-associated thrombosis.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.